HER2 Mutations in Non–Small-Cell Lung Cancer Can Be Continually Targeted

Ronan J. Kelly, Corey Carter, Giuseppe Giaccone, Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab Journal of Clinical Oncology. ,vol. 28, ,(2010) , 10.1200/JCO.2010.29.3126

Kenji Tomizawa, Kenichi Suda, Ryoichi Onozato, Takayuki Kosaka, Hideki Endoh, Yoshitaka Sekido, Hisayuki Shigematsu, Hiroyuki Kuwano, Yasushi Yatabe, Tetsuya Mitsudomi, Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers. Lung Cancer. ,vol. 74, pp. 139- 144 ,(2011) , 10.1016/J.LUNGCAN.2011.01.014

Kurt Beyser, Petra Heinmöller, Josef Rüschoff, Christof Gross, Michele Pedrocchi, Gerd Maass, Claudia Schmidtgen, HER2 status in non-small cell lung cancer: results from patient screening for enrollment to a phase II study of herceptin. Clinical Cancer Research. ,vol. 9, pp. 5238- 5243 ,(2003)

Kristin Bergethon, Alice T. Shaw, Sai-Hong Ignatius Ou, Ryohei Katayama, Christine M. Lovly, Nerina T. McDonald, Pierre P. Massion, Christina Siwak-Tapp, Adriana Gonzalez, Rong Fang, Eugene J. Mark, Julie M. Batten, Haiquan Chen, Keith D. Wilner, Eunice L. Kwak, Jeffrey W. Clark, David P. Carbone, Hongbin Ji, Jeffrey A. Engelman, Mari Mino-Kenudson, William Pao, A. John Iafrate, ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers Journal of Clinical Oncology. ,vol. 30, pp. 863- 870 ,(2012) , 10.1200/JCO.2011.35.6345

Corey J. Langer, Patricia Stephenson, Ann Thor, Mark Vangel, David H. Johnson, Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598 Journal of Clinical Oncology. ,vol. 22, pp. 1180- 1187 ,(2004) , 10.1200/JCO.2004.04.105

Helen J. Ross, George R. Blumenschein,, Joseph Aisner, Nevena Damjanov, Afshin Dowlati, Jennifer Garst, James R. Rigas, Michael Smylie, Habib Hassani, Kimberly E. Allen, Lance Leopold, Tal Z. Zaks, Frances A. Shepherd, Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 16, pp. 1938- 1949 ,(2010) , 10.1158/1078-0432.CCR-08-3328

Marco Gerlinger, Andrew J Rowan, Stuart Horswell, James Larkin, David Endesfelder, Eva Gronroos, Pierre Martinez, Nicholas Matthews, Aengus Stewart, Patrick Tarpey, Ignacio Varela, Benjamin Phillimore, Sharmin Begum, Neil Q McDonald, Adam Butler, David Jones, Keiran Raine, Calli Latimer, Claudio R Santos, Mahrokh Nohadani, Aron C Eklund, Bradley Spencer-Dene, Graham Clark, Lisa Pickering, Gordon Stamp, Martin Gore, Zoltan Szallasi, Julian Downward, P Andrew Futreal, Charles Swanton, None, Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. The New England Journal of Medicine. ,vol. 366, pp. 883- 892 ,(2012) , 10.1056/NEJMOA1113205

Jenn-Yu Wu, Chong-Jen Yu, Yeun-Chung Chang, Chih-Hsin Yang, Jin-Yuan Shih, Pan-Chyr Yang, Effectiveness of Tyrosine Kinase Inhibitors on “Uncommon” Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non–Small Cell Lung Cancer Clinical Cancer Research. ,vol. 17, pp. 3812- 3821 ,(2011) , 10.1158/1078-0432.CCR-10-3408

Jong Woo Lee, Young Hwa Soung, Si Hyung Seo, Su Young Kim, Cho Hyun Park, Young Pil Wang, Kyeongmee Park, Suk Woo Nam, Won Sang Park, Sang Ho Kim, Jung Young Lee, Nam Jin Yoo, Sug Hyung Lee, Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas Clinical Cancer Research. ,vol. 12, pp. 57- 61 ,(2006) , 10.1158/1078-0432.CCR-05-0976